enVVeno Medical Corp (NVNO)
| Market Cap | 5.84M-75.0% |
| Revenue (ttm) | n/a |
| Net Income | -15.72M |
| EPS | -24.99 |
| Shares Out | 694.83K |
| PE Ratio | n/a |
| Forward PE | -1.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,069 |
| Open | 7.98 |
| Previous Close | 8.20 |
| Day's Range | 7.97 - 8.43 |
| 52-Week Range | 7.01 - 33.60 |
| Beta | 1.29 |
| Analysts | none |
| Price Target | 30.00(+257.14%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About NVNO
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NVNO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NVNO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NVNO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NVNO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NVNO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NVNO from public contracts
Source: USAspending.gov
NVNO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NVNO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score